Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.

Therapeutic drug monitoring - 1 Dec 2022

Faraj Pari, Hermansen Astrid, Molden Espen, Hole Kristine

Abstract excerpt

BACKGROUND: Escitalopram is metabolized by CYP2C19 to N-desmethyl escitalopram and escitalopram propionic acid. The primary aims of this study were to investigate the impact of the CYP2C19 phenotype on metabolic ratios of escitalopram in vivo and propose a biomarker for the CYP2C19 phenotype in patients treated with escitalopram. METHODS: Median steady-state serum metabolite/parent drug ratio of N-desmethyl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Citalopram
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Source

Identifiers

PMID: 36372933
DOI: 10.1097/FTD.0000000000000991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.PMID 36372933Read ↗

Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.Semantic proximity Read ↗

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.Semantic proximity Read ↗

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.Semantic proximity Read ↗

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.Semantic proximity Read ↗

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.Semantic proximity Read ↗

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Semantic proximity Read ↗

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.Semantic proximity Read ↗

Preliminary Evidence for Sex Differences in CYP2C19 Metabolic Capacity During Psychotropic Drug Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.